Company intelligence / Profile preview
NovaDigm Therapeutics
Grand Forks, North Dakota, USApmc.ncbi.nlm.nih.gov ↗
- Ownership
- Private
- Employees
- ~11
- Development stage
- Phase 2
01
Overview
Lead vaccine NDV-3 completed two Phase 1 studies in 200 healthy adults and initiated a Phase 1b/2a efficacy study for recurrent vulvovaginal candidiasis. The vaccine demonstrated safety, tolerability, and strong antibody and T-cell immune responses.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Recombinant protein vaccines
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical CenterPevionIstituto Superiore di Sanità
Beyond the preview
Go deeper on NovaDigm Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NovaDigm Therapeutics.